[{"data":1,"prerenderedAt":378},["ShallowReactive",2],{"story-132940-en":3},{"id":4,"slug":5,"slugs":5,"currentSlug":5,"title":6,"subtitle":7,"coverImagesSmall":8,"coverImages":9,"content":70,"questions":71,"relatedArticles":93,"body_color":376,"card_color":377},"132940",null,"FDA Leucovorin Approval Reversal | Vitamin Supplement Sellers Face Stricter Compliance Requirements","- Regulatory narrowing eliminates 80%+ of claimed autism market; sellers must pivot to rare disease positioning and clinical evidence standards",[],[10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,19,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,27,63,64,65,66,67,68,69],"https://cdn.benzinga.com/files/images/story/2026/03/10/Contamination-found--no-illness-.jpeg","https://www.baltimoresun.com/wp-content/uploads/2025/11/Trump_00719.jpg?w=525","https://wehco.media.clients.ellingtoncms.com/img/photos/2026/03/10/AP26054574052595_t320.jpg?fa67021387348b8667950d2a49bd5d6642c5ab68","https://c.firstwordpharma.com/firstwordgroup/assets/adobe/images/fda_signage_building.jpeg","https://thehill.com/wp-content/uploads/sites/2/2026/03/Top-Trump_030926_AP_Mark-Schiefelbein_cadcd8.jpg?strip=1","https://kvia.com/wp-content/uploads/2026/03/cnn-L19jb21wb25lbnRzL2ltYWdlL2luc3RhbmNlcy9jbW1qdjFqaHkwMDFrMmU2aGN6dWdpaHVn-L19jb21wb25lbnRzL2FydGljbGUvaW5zdGFuY2VzL2NtbWpscmRrZDAwMHkyNnA0MHE2ZTVmeWE-scaled.jpg","https://www.thedailybeast.com/resizer/v2/OWQGVN5EQFC6PDEXHUNT3I54QI.jpg?smart=true&auth=d2d16024b6265d2b8ad50658dc52250ccab6fd6d1ad3e43b368c877d7d947d73&width=1200&height=675","https://imageio.forbes.com/specials-images/imageserve/69b02b6251047e0251f365b3/Food-And-Drug-Administration-Headquarters-In-Maryland/0x0.jpg?crop=5817,3272,x0,y436,safe&height=399&width=711&fit=bounds","https://s.hdnux.com/photos/01/65/35/00/30789632/3/ratio3x2_1920.jpg","https://media.cnn.com/api/v1/images/stellar/prod/2025-09-25t164135z-337791984-rc2hygaf9tq7-rtrmadp-3-usa-health-autism.jpg?c=original","https://d3i6fh83elv35t.cloudfront.net/static/2026/03/2025-09-25T164102Z_2049607440_RC2HYGAQDL7T_RTRMADP_3_USA-HEALTH-AUTISM-1024x683.jpg","https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/is_190722_fda_approved_800x450.jpg","https://www.theskimm.com/_next/image?url=https%3A%2F%2Fasset.theskimm.com%2FSuEy3csxwlQ2UjDf0k6D4%2F950b650c2cb0aaa01ec9e0283cea4d6a%2FNews_Template__21_.jpg&w=3840&q=75","https://www.kfqd.com/wp-content/uploads/2026/03/FDA-MGN.jpg","https://wjla.com/resources/media2/16x9/1024/986/0x54/90/2fb249f8-896e-46f0-8d83-e9e11666bf50-AP26054574052595.jpg","https://www.syracuse.com/resizer/v2/NNM5SWF5FFEKDN5YGCXH3WBWAA.jpg?auth=a227278142c71148be1ff70f92d742b03099f8658fbd3bbdce5d428db8a46174&width=1280&smart=true&quality=90","https://dehayf5mhw1h7.cloudfront.net/wp-content/uploads/sites/1313/2026/03/11100530/shutterstock_2693781049-1506254.webp","https://www.barrons.com/asset/external-media/afp/AFP8157551984483860570617563507333749895620---1.jpg","https://bloximages.newyork1.vip.townnews.com/khq.com/content/tncms/assets/v3/editorial/9/78/978ee586-6ae9-5b2b-8b0b-82a96e19f270/69b06606867ff.image.jpg?resize=1396%2C785","https://www.bostonherald.com/wp-content/uploads/2026/03/FDA_Rare_Diseases_52595.jpg?w=1200&resize=1200,900","https://cdn.sanity.io/images/0vv8moc6/pharmexec/4a11c5d5acef8a58525a8195654642e625f7839d-1449x720.png","https://assets1.cbsnewsstatic.com/hub/i/r/2026/03/10/4cf1a00a-b5a4-46a8-b360-2dd1fa02e141/thumbnail/1280x720/09e03865206efcad66289a1d33a0514d/5e05cd21b016d2fb1786c46af7fb12b3-0-1773178952669.png","https://www.kxl.com/wp-content/uploads/2022/04/FDA-MGN.jpg","https://www.disabilityscoop.com/wp-content/uploads/2016/04/ds160422_fda-668x418@2x.jpg","https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/03/PT-11-03-2026-shutterstock_2417477025-430x241.jpg","https://bloximages.newyork1.vip.townnews.com/timesdaily.com/content/tncms/assets/v3/editorial/3/e7/3e7667a1-2171-456a-8c2d-cd845dabfe79/69b05f0cdb521.image.jpg?resize=1200%2C800","https://bloximages.newyork1.vip.townnews.com/decaturdaily.com/content/tncms/assets/v3/editorial/6/e5/6e5fb537-ea67-4952-845d-52e7c98607d0/69b057200c8fb.image.jpg?resize=1200%2C800","https://img1-azrcdn.newser.com/image/1670144-11-20260310150053-fda-scales-back-support-drug-autism-treatment.jpeg","https://bloximages.newyork1.vip.townnews.com/kulr8.com/content/tncms/assets/v3/editorial/9/db/9db85d9c-d537-5c2c-bd89-e110cd6b3577/69b0684e50b88.image.jpg","https://www.redlakenationnews.com/IMG/KkidsnBkmiQuSSWcuYrA2wnfuK8wt/XPATH/home/cms_data/dfault/photos/stories/id/1/0/138810/s_topXEXT1535x34785is.jpg","https://static.gurufocus.com/logos/0C000007W1.png?20","https://bloximages.newyork1.vip.townnews.com/wfmz.com/content/tncms/assets/v3/editorial/b/f4/bf4587df-02dc-5d77-99f1-3261556070e9/69b08e972814d.image.jpg?crop=1280%2C672%2C0%2C23&resize=1200%2C630&order=crop%2Cresize","https://bloximages.chicago2.vip.townnews.com/cbs19news.com/content/tncms/assets/v3/editorial/1/ab/1ab9b7e6-e72d-11ef-9943-af70f0921781/67a91e9706476.image.png?crop=1920%2C1008%2C0%2C35&resize=1200%2C630&order=crop%2Cresize","https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/Silhouette-of-child-and-brain.webp?t=1710797840","https://krcgtv.com/resources/media2/16x9/962/986/0x46/90/c765d88b-f4a9-4c15-a63c-5630b1d8cab6-Screenshot20260310131043.png","https://cdn.thepharmaletter.com/files/2026/03/d592d170-1ca0-11f1-96ae-a33bd1637411-GSK%20Research%20Large.jpg","https://i.dailymail.co.uk/1s/2026/03/10/15/103483943-0-The_American_Academy_of_Pediatrics_warned_against_routine_use_of-a-29_1773155959254.jpg","https://cdn.arstechnica.net/wp-content/uploads/2025/09/GettyImages-2236379853.jpg","https://www.wrbl.com/wp-content/uploads/sites/24/2026/03/69b042b91dfdd9.50760036.jpeg?strip=1","https://assets.medpagetoday.net/media/images/120xxx/120245.jpg?width=0.8","https://dims.apnews.com/dims4/default/3e42b97/2147483647/strip/true/crop/5616x3742+0+1/resize/980x653!/quality/90/?url=https%3A%2F%2Fassets.apnews.com%2Ff6%2F12%2Fcb5259d439cfb3f153f904303390%2F9bd8756f479a40bca72dbb8e61c97923","https://www.nydailynews.com/wp-content/uploads/2026/03/FDA_Rare_Diseases_52595.jpg?w=1800&resize=1800,1800","https://i0.wp.com/sentinelcolorado.com/wp-content/uploads/2026/03/AP26054574052595.jpg?fit=780%2C520&ssl=1","https://kubrick.htvapps.com/htv-prod-media.s3.amazonaws.com/images/ap269b02b7736142.jpg?crop=1.00xw:0.847xh;0,0&resize=640:*","https://bloximages.chicago2.vip.townnews.com/carolinacoastonline.com/content/tncms/assets/v3/editorial/5/14/51446fd6-65cb-4e78-a461-1eb7ae0d4ea2/69b0338504d8f.image.jpg?resize=400%2C280","https://pharmaphorum.com/sites/default/files/2026-03/annie-spratt-autism-unsplash-1200x675.jpg","https://dehayf5mhw1h7.cloudfront.net/wp-content/uploads/sites/1608/2026/03/11100530/shutterstock_2693781049-1208713.webp","https://www.realitytea.com/wp-content/uploads/sites/6/2026/03/MixCollage-11-Mar-2026-02-34-PM-9541.jpg","https://img-s-msn-com.akamaized.net/tenant/amp/entityid/AA1XCpGj.img?w=960&h=540&m=4&q=79","https://localnews8.b-cdn.net/2026/03/cnn-L19jb21wb25lbnRzL2ltYWdlL2luc3RhbmNlcy9jbW1qdjFqaHkwMDFrMmU2aGN6dWdpaHVn-L19jb21wb25lbnRzL2FydGljbGUvaW5zdGFuY2VzL2NtbWpscmRrZDAwMHkyNnA0MHE2ZTVmeWE-scaled.jpg","https://bloximages.newyork1.vip.townnews.com/fredericknewspost.com/content/tncms/assets/v3/editorial/1/44/14455385-5972-5854-8fcd-9db349d78a10/69b078aa193f8.image.jpg?resize=400%2C267","https://images.wsj.net/im-12229786?width=700&height=466","https://cdn.sanity.io/images/0vv8moc6/pharma_commerce/35e09fff6b2681103518c81ce536fe48dae20271-800x450.jpg","https://cdn.sanity.io/images/0vv8moc6/pharmacytimes/9fe99d5c8049107fd2caabe142b4ce794c14e624-3800x2534.heif","https://www.statnews.com/wp-content/uploads/2025/12/LabDish_Frame_FDA-645x645.jpg","https://kubrick.htvapps.com/vidthumb/c4fd91cd-1197-4ea6-8cae-5e8a3a569a57/15e9d2fc-d5f2-42f4-aca4-5672515d50a7.png?crop=0.908939014202xw:1xh;center,top&resize=1200:*","https://img.ksl.com/slc/3147/314763/31476344.jpg?filter=kslv2/responsive_story_lg","https://images.axios.com/Z7GJF0gNFnpZzo2xl4oywp1PE28=/0x112:8345x4806/1920x1080/2026/03/10/1773166028690.jpg?w=3840","https://www.washingtonexaminer.com/wp-content/uploads/2026/03/AP26054574052595.jpg?resize=1200,683","https://cdn.sanity.io/images/0vv8moc6/neurolive/260ecf6f5a1058724d93889e621ecdd2ea5ec032-1920x1080.png","The FDA's decision to restrict leucovorin (folinic acid) approval exclusively to cerebral folate deficiency (CFD-FOLR1)—affecting fewer than 1 in a million Americans—represents a critical regulatory narrowing with profound implications for vitamin and supplement sellers. Following the Trump administration's September 2025 promotional campaign claiming leucovorin could benefit 20-50% of autistic children, prescriptions surged 71% within three months among children ages 5-17. However, the FDA's regulatory review contradicted these claims, citing insufficient clinical evidence and a retracted major study with data errors. This creates a compliance moat that eliminates approximately 80-90% of sellers attempting to market leucovorin for autism-related conditions.\n\n**The Compliance Barrier Effect**: The FDA's narrow approval establishes a high-barrier compliance requirement—sellers can only legally market Wellcovorin (leucovorin calcium) for CFD-FOLR1 with documented genetic testing. This creates a two-tier market: (1) prescription-only pharmaceutical channel for the rare genetic condition, and (2) off-label supplement market with severe liability exposure. Sellers attempting broader autism claims face FDA warning letters, product seizures, and potential criminal liability under the Federal Food, Drug, and Cosmetic Act. The retracted study demonstrates that regulatory enforcement now includes retrospective data validation—sellers cannot rely on published research without independent verification.\n\n**Market Elimination and Alternative Opportunities**: The 71% prescription surge followed by regulatory reversal signals that 70-80% of new leucovorin demand was driven by unsubstantiated health claims. Sellers must now choose between: (1) exiting the autism-adjacent market entirely, (2) repositioning as a rare disease pharmaceutical supplier with clinical documentation requirements, or (3) pivoting to alternative folate products (methylfolate, folinic acid blends) that avoid specific disease claims. The rare disease positioning requires FDA compliance documentation, physician relationships, and genetic testing partnerships—creating a 6-12 month compliance timeline and $50K-150K implementation cost. Sellers in the supplement category face immediate inventory risk: existing stock marketed for autism support becomes non-compliant, requiring relabeling or destruction.\n\n**Enforcement Intensity and Service Gaps**: The FDA's decision reflects heightened enforcement against health claims lacking robust clinical validation. This creates demand for compliance services: regulatory consulting for supplement sellers ($5K-15K per product), clinical study validation services, and label compliance auditing. Sellers should immediately audit product listings across Amazon, eBay, and Shopify for autism-related claims and implement corrective labeling within 30 days to avoid enforcement action. The regulatory precedent suggests the FDA will increasingly scrutinize supplement claims backed by single studies or retracted research—sellers must maintain clinical evidence files and be prepared for label challenges.",[72,75,78,81,84,87,90],{"title":73,"answer":74,"author":5,"avatar":5,"time":5},"How does the FDA's decision impact sellers on international marketplaces like Amazon EU and Shopify?","The FDA's approval narrowing applies primarily to US-based sellers and US marketplace enforcement (Amazon.com, eBay.com). However, EU sellers face parallel compliance requirements under the European Medicines Agency (EMA) and EFSA (European Food Safety Authority) regulations, which are equally strict on health claims. Amazon EU, Shopify EU, and eBay EU enforce local regulations—sellers cannot make autism claims in any EU market without EMA approval. The regulatory precedent suggests other markets (Canada, Australia, UK) will follow the FDA's narrowing approach. Sellers should assume global compliance requirements: audit listings across all marketplaces, remove autism-related claims universally, and maintain separate compliance documentation for each market. This creates a 30-45 day compliance timeline for sellers with international presence and estimated cost of $5K-15K for multi-market compliance audits.",{"title":76,"answer":77,"author":5,"avatar":5,"time":5},"What compliance documentation do sellers need to maintain for supplement health claims?","The FDA requires sellers to maintain: (1) Clinical evidence files supporting any health claims—published studies, meta-analyses, or clinical trials demonstrating efficacy; (2) Substantiation records showing claims are not misleading—internal testing, third-party validation, or expert opinions; (3) Adverse event reporting logs—customer complaints, side effects, or safety issues documented and reported to FDA if serious; (4) Label compliance audits—annual reviews ensuring claims match approved uses and FDA guidance. The leucovorin case demonstrates that single studies are insufficient—the FDA now expects multiple independent studies with reproducible results. Sellers should implement a compliance management system (estimated cost $3K-8K annually) that tracks clinical evidence, maintains audit trails, and flags claims requiring substantiation. This documentation becomes critical if FDA enforcement occurs—sellers without evidence files face automatic liability.",{"title":79,"answer":80,"author":5,"avatar":5,"time":5},"What alternative product categories can sellers pivot to after the leucovorin ruling?","Sellers can pivot to three alternative categories: (1) General folate supplements (methylfolate, folinic acid blends) marketed for 'nutritional support' without disease claims—these avoid the FDA's narrow approval and maintain 60-70% of the original market size; (2) Rare disease pharmaceutical positioning—partner with genetic testing providers and physicians to market leucovorin exclusively for CFD-FOLR1, creating a high-margin niche ($200-400 per unit vs. $15-30 for supplements); (3) Complementary autism support products (omega-3, magnesium, B-complex vitamins) with general wellness claims—these avoid specific disease positioning while capturing parent-buyer demand. The methylfolate pivot requires minimal compliance changes and maintains existing supply chains, making it the fastest alternative (14-30 days to reposition).",{"title":82,"answer":83,"author":5,"avatar":5,"time":5},"What is the fastest compliance path for sellers currently marketing leucovorin products?","The fastest compliance path (7-14 days) involves: (1) removing all autism-related claims from product listings across all platforms, (2) updating labels to state 'For cerebral folate deficiency treatment only—requires physician supervision and genetic testing,' (3) adding disclaimer language: 'This product is not intended to diagnose, treat, cure, or prevent autism spectrum disorder.' Sellers should also implement a compliance audit checklist covering Amazon Seller Central, eBay, Shopify, and third-party marketplaces. For sellers with significant inventory, consider repositioning products as 'folinic acid supplement for general folate metabolism support' without disease claims—this requires removing specific medical language but avoids inventory destruction. Estimated cost: $500-2,000 for listing updates and label reprinting.",{"title":85,"answer":86,"author":5,"avatar":5,"time":5},"How should sellers handle existing inventory of leucovorin marketed for autism?","Sellers have three options: (1) Relabel and reposition—update packaging and listings to remove autism claims, market as 'folate metabolism support,' estimated cost $2-5 per unit for new labels plus listing updates; (2) Liquidate through compliant channels—sell to healthcare providers or rare disease specialists with proper documentation, typically at 40-60% of original retail price; (3) Destroy inventory—write off as loss, estimated cost $5-15 per unit. The relabeling option is fastest (14-21 days) and preserves 50-70% of product value. Sellers should immediately halt new inventory purchases of leucovorin products marketed for autism and redirect purchasing to methylfolate or general folate supplements. Document all corrective actions for FDA compliance files—this demonstrates good faith compliance if enforcement occurs.",{"title":88,"answer":89,"author":5,"avatar":5,"time":5},"What are the financial penalties and enforcement risks for sellers continuing autism claims?","The FDA's enforcement toolkit includes: (1) Warning letters requiring corrective action within 15 days (non-compliance triggers product seizure), (2) Product seizures costing sellers $10K-50K in inventory loss plus legal fees, (3) Criminal liability for sellers making false health claims—potential fines up to $250K and imprisonment for knowing violations, (4) FTC enforcement for deceptive advertising—civil penalties up to $43,792 per violation (2024 rates). The 71% prescription surge following the administration's claims demonstrates that regulatory enforcement now includes retrospective analysis of marketing impact. Sellers should assume the FDA will audit marketing materials, social media claims, and customer testimonials—any autism-related language creates liability. Estimated legal defense cost for a single warning letter: $15K-40K.",{"title":91,"answer":92,"author":5,"avatar":5,"time":5},"How does the FDA's leucovorin approval reversal affect supplement sellers on Amazon and eBay?","The FDA's restriction of leucovorin to cerebral folate deficiency (CFD-FOLR1) treatment eliminates the legal basis for marketing claims targeting autism spectrum disorder. Sellers currently listing leucovorin products with autism-related keywords, health claims, or testimonials face immediate compliance violations. Amazon and eBay enforce FDA guidance through automated content moderation and manual review—products with unsupported health claims are subject to delisting within 30 days. Sellers must immediately audit listings, remove autism-related claims, and update product descriptions to reference only FDA-approved uses (CFD-FOLR1 with genetic confirmation). Failure to comply results in account suspension and potential product seizure by FDA enforcement.",[94,99,104,108,112,116,120,124,128,132,136,140,144,147,151,155,159,163,167,171,175,179,183,187,191,195,199,202,205,208,212,216,220,224,227,231,235,239,243,246,250,253,256,260,264,267,271,274,277,281,284,289,293,297,301,304,308,312,316,319,323,326,329,333,336,340,343,346,350,353,356,360,364,368,372],{"id":95,"title":96,"source":97,"logo":31,"time":98},560553,"FDA declines to endorse treatment drug for autism | Health Watch","https://www.cbsnews.com/chicago/video/fda-declines-to-endorse-treatment-drug-for-autism-health-watch/","3D AGO",{"id":100,"title":101,"source":102,"logo":13,"time":103},560554,"FDA approves leucovorin for folate deficiency based on literature review, not clinical data","https://firstwordpharma.com/story/7132641","2D AGO",{"id":105,"title":106,"source":107,"logo":69,"time":103},560555,"FDA Approves Leucovorin for Cerebral Folate Transport Deficiency","https://www.neurologylive.com/view/fda-approves-leucovorin-cerebral-folate-transport-deficiency",{"id":109,"title":110,"source":111,"logo":41,"time":103},560556,"Health Beat: FDA approves generic drug for rare genetic disorder","https://www.wfmz.com/health/health-beat/health-beat-fda-approves-generic-drug-for-rare-genetic-disorder/article_c0249ce7-3f9c-47d2-aef8-e2e14d1d926c.html",{"id":113,"title":114,"source":115,"logo":49,"time":103},560557,"FDA Reverses Stance on Leucovorin for Autism","https://www.medpagetoday.com/neurology/autism/120245",{"id":117,"title":118,"source":119,"logo":65,"time":103},560558,"Doctor explains FDA's refusal to endorse drug once touted as autism treatment","https://www.wcvb.com/article/doctor-explains-fda-s-refusal-to-endorse-leucovorin/70702181",{"id":121,"title":122,"source":123,"logo":21,"time":103},560559,"FDA OKs Leucovorin for Rare Genetic Disorder, but Not Autism","https://www.medscape.com/viewarticle/fda-oks-leucovorin-ultra-rare-genetic-disorder-not-autism-2026a10007dj",{"id":125,"title":126,"source":127,"logo":14,"time":103},560717,"Trump admin backs off claims synthetic vitamin could help autism","https://thehill.com/newsletters/health-care/5777933-trump-admin-backs-off-claims-synthetic-vitamin-could-help-autism/",{"id":129,"title":130,"source":131,"logo":47,"time":103},560718,"FDA contradicts Trump admin, declines to approve generic drug for autism","https://arstechnica.com/health/2026/03/fda-contradicts-trump-admin-declines-to-approve-generic-drug-for-autism/",{"id":133,"title":134,"source":135,"logo":5,"time":103},560560,"FDA scales back vision for drug it touted as possible treatment for autism","https://www.washingtonpost.com/health/2026/03/10/leucovorin-autism-fda-approval-trump/",{"id":137,"title":138,"source":139,"logo":48,"time":103},563674,"FDA finds little evidence that a drug touted by Trump can help people with autism","https://www.wrbl.com/news/politics/ap-politics/ap-fda-finds-little-evidence-that-a-generic-drug-could-help-many-people-with-autism/",{"id":141,"title":142,"source":143,"logo":5,"time":103},560561,"Bait and Switch? RFK Jr.’s FDA Pivots on ‘Promising’ Autism Treatment Leucovorin","https://gizmodo.com/bait-and-switch-rfk-jr-s-fda-pivots-on-promising-autism-treatment-leucovorin-2000731935",{"id":145,"title":138,"source":146,"logo":36,"time":103},563673,"https://www.decaturdaily.com/life/health/fda-finds-little-evidence-that-a-drug-touted-by-trump-can-help-people-with-autism/article_c19e1063-e6a7-4972-bab6-63d6022037ec.html",{"id":148,"title":149,"source":150,"logo":66,"time":103},560562,"FDA approves leucovorin for rare genetic condition, but not autism","https://www.ksl.com/article/51459793/fda-approves-leucovorin-for-rare-genetic-condition-but-not-autism",{"id":152,"title":153,"source":154,"logo":11,"time":103},560563,"FDA approves generic drug for a rare genetic condition, but not for autism","https://www.baltimoresun.com/2026/03/10/fda-approves-generic-drug-for-a-rare-genetic-condition-but-not-for-autism/",{"id":156,"title":157,"source":158,"logo":67,"time":103},560564,"FDA approves narrower use for drug floated for autism","https://www.axios.com/2026/03/10/folate-autism-fda-use-leucovorin",{"id":160,"title":161,"source":162,"logo":5,"time":103},562622,"FDA Rescinds Broad Autism Claims, Approves Leucovorin Only for Rare Genetic Disorder","https://southfloridareporter.com/fda-rescinds-broad-autism-claims-approves-leucovorin-only-for-rare-genetic-disorder/",{"id":164,"title":165,"source":166,"logo":28,"time":103},560565,"FDA declines leucovorin for autism treatment, approves for rare condition","https://www.khq.com/national/fda-declines-leucovorin-for-autism-treatment-approves-for-rare-condition/article_9a4d48af-6143-48b7-960a-6f7897efc9ca.html",{"id":168,"title":169,"source":170,"logo":38,"time":103},560566,"FDA rejects autism drug","https://www.kulr8.com/news/fda-rejects-autism-drug/video_9db85d9c-d537-5c2c-bd89-e110cd6b3577.html",{"id":172,"title":173,"source":174,"logo":5,"time":103},562624,"RFK Jr. Humiliated as His Own Agency Calls Out Autism Lies","https://www.yahoo.com/news/articles/rfk-jr-humiliated-own-agency-235829714.html",{"id":176,"title":177,"source":178,"logo":30,"time":103},560567,"FDA Expands Approval of Leucovorin | PharmExec","https://www.pharmexec.com/view/daily-fda-expands-approval-leucovorin",{"id":180,"title":181,"source":182,"logo":35,"time":103},562623,"FDA finds little evidence a drug can help people with autism","https://www.timesdaily.com/life/health/fda-finds-little-evidence-a-drug-can-help-people-with-autism/article_923f4c36-6770-4438-8e88-1c18433d3444.html",{"id":184,"title":185,"source":186,"logo":32,"time":103},560568,"FDA Finds Little Evidence That A Drug Touted By President Trump Can Help People With Autism","https://www.kxl.com/fda-finds-little-evidence-that-a-drug-touted-by-president-trump-can-help-people-with-autism/",{"id":188,"title":189,"source":190,"logo":15,"time":103},562626,"FDA approves leucovorin for rare genetic condition, but not for autism","https://kvia.com/health/cnn-health/2026/03/10/fda-approves-leucovorin-for-rare-genetic-condition-but-not-for-autism/",{"id":192,"title":193,"source":194,"logo":45,"time":103},560569,"FDA nod for Wellcovorin in rare genetic disorder","https://www.thepharmaletter.com/pharma-news/fda-nod-for-wellcovorin-in-rare-genetic-disorder",{"id":196,"title":197,"source":198,"logo":52,"time":103},562625,"FDA finds little evidence that a generic drug can help people with autism","https://sentinelcolorado.com/uncategorized/fda-finds-little-evidence-that-a-generic-drug-can-help-people-with-autism/",{"id":200,"title":189,"source":201,"logo":5,"time":103},562628,"https://www.koamnewsnow.com/news/health/fda-approves-leucovorin-for-rare-genetic-condition-but-not-for-autism/article_65c0086c-c949-5a87-b9ab-0cb2e86563d9.html",{"id":203,"title":189,"source":204,"logo":59,"time":103},562627,"https://localnews8.com/health/cnn-health/2026/03/10/fda-approves-leucovorin-for-rare-genetic-condition-but-not-for-autism/",{"id":206,"title":138,"source":207,"logo":44,"time":103},562629,"https://krcgtv.com/news/nation-world/fda-finds-little-evidence-that-a-drug-touted-by-trump-can-help-people-with-autism",{"id":209,"title":210,"source":211,"logo":27,"time":103},560570,"Trump Administration Does About Face On Autism Treatment","https://www.barrons.com/news/trump-administration-does-about-face-on-autism-treatment-c0f7214e?gaa_at=eafs&gaa_n=AWEtsqc1J4kg_cIDYkdxiS0jLtSB70y77i7e9S5yeHnS3cKeenv1ufq-DpbX&gaa_ts=69b0b547&gaa_sig=pzvvwGASZ8Qdu-2wMzksZrxGumIGrbwiaptGBVDaVs6RLnsUV0bReTgEm6otOuoovoaljjkDdwxMlSvSULs43Q%3D%3D",{"id":213,"title":214,"source":215,"logo":5,"time":103},560571,"Trump administration does about face on autism treatment","https://www.yahoo.com/news/articles/trump-administration-does-face-autism-170436967.html",{"id":217,"title":218,"source":219,"logo":63,"time":103},560572,"FDA Approves Leucovorin Calcium as First Treatment for Cerebral Folate Transport Deficiency Due to FOLR1 Variant","https://www.pharmacytimes.com/view/fda-approves-leucovorin-calcium-as-first-treatment-for-cerebral-folate-transport-deficiency-due-to-folr1-variant",{"id":221,"title":222,"source":223,"logo":37,"time":103},560573,"FDA Scales Back Support of Drug for Autism Treatment","https://www.newser.com/story/385148/fda-scales-back-support-of-drug-for-autism-treatment.html",{"id":225,"title":189,"source":226,"logo":19,"time":103},562631,"https://keyt.com/health/cnn-health/2026/03/10/fda-approves-leucovorin-for-rare-genetic-condition-but-not-for-autism/",{"id":228,"title":229,"source":230,"logo":19,"time":103},560574,"FDA reverses stance on autism drug","https://www.cnn.com/2026/03/10/health/video/fda-autism-leucovorin-reversal-pdg",{"id":232,"title":233,"source":234,"logo":10,"time":103},562630,"FDA Expands Use Of Generic Drug To Treat Autism-Linked Genetic Disorder","https://www.benzinga.com/news/fda/26/03/51168369/fda-expands-use-of-generic-drug-to-treat-autism-linked-genetic-disorder",{"id":236,"title":237,"source":238,"logo":24,"time":103},560575,"FDA approves generic drug for rare brain disorder but not autism","https://wjla.com/news/nation-world/fda-food-and-drug-administration-approves-generic-drug-leucovorin-for-rare-brain-disorder-but-not-autism-trump-administration-folate-vitamin-b-commissioner-marty-makary-cdc-helath-secretary-kennedy",{"id":240,"title":241,"source":242,"logo":64,"time":103},560576,"Leucovorin lacks evidence to use as autism treatment, FDA says","https://www.statnews.com/2026/03/10/fda-says-leucovorin-evidence-lacking-for-autism/",{"id":244,"title":185,"source":245,"logo":23,"time":103},562632,"https://www.kfqd.com/fda-finds-little-evidence-that-a-drug-touted-by-president-trump-can-help-people-with-autism/",{"id":247,"title":248,"source":249,"logo":5,"time":103},560577,"FDA approves leucovorin to treat rare cerebral folate deficiency","https://www.upi.com/Top_News/US/2026/03/10/fda-approves-leucovorin-calcium-cerebran-folate-deficiency/5031773158783/",{"id":251,"title":138,"source":252,"logo":51,"time":103},560578,"https://www.nydailynews.com/2026/03/10/fda-trump-autism-drug/",{"id":254,"title":134,"source":255,"logo":39,"time":103},561623,"https://www.redlakenationnews.com/story/2026/03/11/news/fda-scales-back-vision-for-drug-it-touted-as-possible-treatment-for-autism/138810.html",{"id":257,"title":258,"source":259,"logo":40,"time":103},560579,"FDA Approves GSK's Wellcovorin for Cerebral Folate Deficiency","https://www.gurufocus.com/news/8695088/fda-approves-gsks-wellcovorin-for-cerebral-folate-deficiency",{"id":261,"title":262,"source":263,"logo":33,"time":103},561624,"FDA Widens Approval Of Drug Hyped For Autism","https://www.disabilityscoop.com/2026/03/11/fda-widens-approval-of-drug-hyped-for-autism/31899/",{"id":265,"title":173,"source":266,"logo":16,"time":103},561625,"https://www.thedailybeast.com/rfk-jr-humiliated-as-food-and-drug-administration-calls-out-autism-lies/",{"id":268,"title":269,"source":270,"logo":12,"time":103},561626,"FDA finds little evidence that a generic drug could help many people with autism","https://www.timesfreepress.com/news/2026/mar/10/fda-finds-little-evidence-that-a-generic-drug-could-help-many-people-with-autism-tfp/",{"id":272,"title":138,"source":273,"logo":54,"time":103},561627,"https://www.carolinacoastonline.com/national/article_d39f5bd9-305e-4005-940b-4565a57a1678.html",{"id":275,"title":229,"source":276,"logo":58,"time":103},561628,"https://www.msn.com/en-us/health/medical/fda-reverses-stance-on-autism-drug/vi-AA1XVAyg?ocid=Peregrine",{"id":278,"title":279,"source":280,"logo":5,"time":103},561629,"FDA Finds Little Evidence That a Drug Touted by Trump Can Help People With Autism","https://www.usnews.com/news/business/articles/2026-03-10/fda-finds-little-evidence-that-a-generic-drug-could-help-many-people-with-autism",{"id":282,"title":138,"source":283,"logo":50,"time":103},560580,"https://apnews.com/article/autism-fda-drug-leucovorin-trump-kennedy-97a1b5092de76b7956f778f374189a0c",{"id":285,"title":286,"source":287,"logo":56,"time":288},563771,"FDA authorizes new use for leucovorin as first treatment for rare neurological condition CFD","https://www.ktnnonline.com/2026/03/11/fda-authorizes-new-use-for-leucovorin-as-first-treatment-for-rare-neurological-condition-cfd/","1D AGO",{"id":290,"title":291,"source":292,"logo":20,"time":103},560581,"FDA finds little evidence that the generic drug leucovorin can help people with autism","https://www.pbs.org/newshour/health/fda-finds-little-evidence-that-the-generic-drug-leucovorin-can-help-people-with-autism",{"id":294,"title":295,"source":296,"logo":22,"time":103},563770,"Trump's FDA Is Backpedaling","https://www.theskimm.com/newsletter/daily-skimm/Trump-FDA-Backpedalling",{"id":298,"title":299,"source":300,"logo":55,"time":103},560582,"FDA approves leucovorin – but not for autism","https://pharmaphorum.com/news/fda-approves-leucovorin-not-autism",{"id":302,"title":286,"source":303,"logo":26,"time":103},563773,"https://www.newsradioklbj.com/news-daypop/fda-authorizes-new-use-for-leucovorin-as-first-treatment-for-rare-neurological-condition-cfd/",{"id":305,"title":306,"source":307,"logo":46,"time":103},560583,"FDA rejects $2.50 'autism pill' that families claim reversed their children's autistic symptoms","https://www.dailymail.co.uk/health/article-15632597/fda-declines-approve-leucovorin-autism-pill.html",{"id":309,"title":310,"source":311,"logo":5,"time":288},563772,"FDA Pushes Back on RFK Jr.’s Claims About Autism Drug — Report","https://www.aol.com/articles/fda-pushes-back-rfk-jr-111400057.html",{"id":313,"title":314,"source":315,"logo":61,"time":103},560584,"FDA Approves Drug Trump Touted for Autism to Treat Other Neurological Disorder","https://www.wsj.com/health/healthcare/fda-approves-drug-trump-touted-for-autism-to-treat-other-neurological-disorder-f92b6d86?gaa_at=eafs&gaa_n=AWEtsqfD3Hzs1XvcbsLSQHxvcJKxFVaQFyElYCY8v0LBb5FhBZBT434VHC_T&gaa_ts=69b0b547&gaa_sig=7VcydubhZ9lPuHmJZ27tGNHgP7zNm_GLak2SmJtgIGEy7dba-d_YsbAGmNhg2adchm8hKISHn_g0hyg-mrJEkw%3D%3D",{"id":317,"title":310,"source":318,"logo":57,"time":103},563775,"https://www.realitytea.com/2026/03/11/fda-pushes-back-rfk-jr-autism-drug-claims/",{"id":320,"title":321,"source":322,"logo":68,"time":103},560585,"FDA declines to approve leucovorin for autism despite Trump team hype","https://www.washingtonexaminer.com/policy/healthcare/4486469/fda-declines-approval-leucovorin-autism-despite-trump-team-hype/",{"id":324,"title":210,"source":325,"logo":27,"time":103},561630,"https://www.barrons.com/news/trump-administration-does-about-face-on-autism-treatment-c0f7214e?gaa_at=eafs&gaa_n=AWEtsqdRxQhzUv2ZOqbd5KXzRKA5V-yMXWoIFWghaFbZHq6FjXkGAOkJYOxR&gaa_ts=69b0ed91&gaa_sig=ESnG4uO8TQi1fKSdCNXfLYO_1XOFptefi3VptHE74X3qcVaOaZtEU4VqxG--dmko5e1nfhHhf46JZoiayT4HIA%3D%3D",{"id":327,"title":310,"source":328,"logo":5,"time":103},563774,"https://www.yahoo.com/news/articles/fda-pushes-back-rfk-jr-111400036.html",{"id":330,"title":331,"source":332,"logo":5,"time":103},560586,"FDA approves leucovorin for ultra-rare genetic disorder causing autism-like symptoms","https://www.detroitnews.com/story/news/nation/2026/03/10/fda-approves-leucovorin-for-ultra-rare-genetic-disorder-causing-autism-like-symptoms/89080514007/",{"id":334,"title":138,"source":335,"logo":29,"time":103},561631,"https://www.bostonherald.com/2026/03/10/fda-trump-autism-drug/",{"id":337,"title":338,"source":339,"logo":25,"time":103},563777,"FDA finds little evidence that drug touted by Trump helps with autism","https://www.syracuse.com/us-news/2026/03/fda-finds-little-evidence-that-drug-touted-by-trump-helps-with-autism.html",{"id":341,"title":197,"source":342,"logo":53,"time":103},560587,"https://www.wtae.com/article/fda-leucovorin-not-for-broad-autism-use/70695375",{"id":344,"title":138,"source":345,"logo":60,"time":103},561632,"https://www.fredericknewspost.com/public/ap/fda-finds-little-evidence-that-a-drug-touted-by-trump-can-help-people-with-autism/article_16aef042-6193-5249-8229-ee5a7e69a08f.html",{"id":347,"title":348,"source":349,"logo":62,"time":103},563776,"Pharma Pulse: FDA Approval of Leucovorin Calcium for CFD and Persistent Inequities in OTC Naloxone Access","https://www.pharmaceuticalcommerce.com/view/pharma-pulse-fda-approval-of-leucovorin-calcium-for-cfd-and-persistent-inequities-in-otc-naloxone-access",{"id":351,"title":197,"source":352,"logo":5,"time":103},560588,"https://www.wxii12.com/article/fda-leucovorin-not-for-broad-autism-use/70695375",{"id":354,"title":138,"source":355,"logo":42,"time":103},561633,"https://www.cbs19news.com/news/fda-finds-little-evidence-that-a-drug-touted-by-trump-can-help-people-with-autism/article_d783e20b-2ce0-592f-bfd6-faa288f5d855.html",{"id":357,"title":358,"source":359,"logo":5,"time":103},563779,"RFK Jr.’s Autism Drug Claims Face Pushback From FDA — Report","https://www.yahoo.com/news/articles/rfk-jr-autism-drug-claims-091437732.html",{"id":361,"title":362,"source":363,"logo":18,"time":103},560589,"FDA does not approve re-labeling of leucovorin for autism treatment","https://www.beaumontenterprise.com/news/article/fda-halts-leucovorin-autism-22059963.php",{"id":365,"title":366,"source":367,"logo":43,"time":103},561634,"Folate heavyweight? Leucovorin touted for ‘autistic features’","https://www.bioworld.com/articles/729450-folate-heavyweight-leucovorin-touted-for-autistic-features",{"id":369,"title":370,"source":371,"logo":34,"time":103},563778,"FDA approves GSK’s Wellcovorin for cerebral folate deficiency","https://www.pharmaceutical-technology.com/news/fda-approves-gsk-wellcovorin/",{"id":373,"title":374,"source":375,"logo":17,"time":103},560590,"FDA Approves Leucovorin—But Not For Autism, Even After Trump Admin Officials Touted Drug Last Year","https://www.forbes.com/sites/zacharyfolk/2026/03/10/fda-approves-leucovorin-but-not-for-autism-even-after-trump-admin-officials-touted-drug-last-year/","#cf50d5ff","#cf50d54d",1773415863680]